Align Technology stock sheds 5% on weak Q4 revenue outlook

Align Technology (ALGN) reported Q3 2026 earnings beating estimates with $2.80 EPS and $1.02B revenue, but shares fell 5% due to Q4 guidance below expectations. Q4 revenue forecasted at $1.00-$1.02B vs. $1.05B consensus. Full-year revenue expected at $4.11-$4.13B vs. $4.15B estimate. Clear Aligner revenues rose 4.2% YoY, while Imaging Systems revenues declined 7.6% YoY.

Original reporting
Published Oct 28, 2026, 8:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ALGN
Bearish
high confidence
Mentioned
$ALGN
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ALGNBearishHigh
01

Why it matters

The guidance shortfall is the primary catalyst for the price move; margin expansion and share buyback provide some upside potential.

02

Market read

First report of earnings and guidance for a large‑cap healthcare equipment company; material for traders.

03

What to watch

Strong Clear Aligner volume growth and improved margins may offset guidance concerns.

Relevance 8/10Novelty 8/10Timing: after‑hours today

Background

Align Technology reported Q3 FY2026 results that beat EPS and revenue estimates, but issued Q4 guidance below consensus, prompting a 5% after‑hours decline.

Company-level read

Ticker impact

$ALGNBearishHigh confidence
Context

Shares fell 5% after hours as Q4 revenue guidance of $1.00‑$1.02B missed consensus of $1.05B.

Expected impact

downward pressure as investors price in lower revenue outlook

Evidence & confidence

Guidance shortfall is material for a large‑cap dental device maker and triggered an immediate 5% drop.

Market effects

Dental and orthodontic equipment sector may see broader pressure on peers.

U.S. equity markets could see modest downside in healthcare equipment stocks.

Limited to markets tracking Align Technology and related suppliers.

Counterpoint

The $300 M share‑repurchase program could support the price if executed aggressively.

Key entities

  • Align Technology, Inc.

    Dental device maker that reported Q3 results and issued Q4 guidance.

Related articles

$ALGNMed

Align Technology Inc (ALGN) Q3 2026 Earnings Call Highlights: Record Doctor Submitters

Align Technology (ALGN) reported Q3 2026 earnings with record 91,000 doctor submitters (+3% YoY) and Clear Aligner shipments up 6.6% to 691,000. Non-GAAP operating margin was 24.4%, exceeding outlook. Revenue growth slowed to 1.9% YoY, with Systems & Services revenue down 7.6%. ASP declined 2.3% YoY. Q4 guidance was reduced due to consumer challenges and lower ASP assumptions. The company highlighted innovation in sports mouthguards and margin improvement plans for 2027.

$ALGNMedAI 8/10

ALGN Q3 Earnings & Revenues Beat, '26 Sales View Down, Stock Falls

Align Technology (ALGN) reported Q3 2026 earnings of $2.80 per share, up 7.3% YoY, and revenues of $1.01B, up 1.9% YoY. Clear Aligner shipments increased 6.6% YoY. ALGN shares fell 0.7% post-earnings. The company lowered its 2026 revenue outlook, citing softer expectations for Systems and Services business. Q4 revenue guidance is $1.00-$1.02B, below consensus of $1.05B.